165 related articles for article (PubMed ID: 30170240)
21. The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies.
Rubio I; Seitz H; Canali E; Sehr P; Bolchi A; Tommasino M; Ottonello S; Müller M
Virology; 2011 Jan; 409(2):348-59. PubMed ID: 21074234
[TBL] [Abstract][Full Text] [Related]
22. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
23. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.
Alphs HH; Gambhira R; Karanam B; Roberts JN; Jagu S; Schiller JT; Zeng W; Jackson DC; Roden RB
Proc Natl Acad Sci U S A; 2008 Apr; 105(15):5850-5. PubMed ID: 18413606
[TBL] [Abstract][Full Text] [Related]
24. A protective and broadly cross-neutralizing epitope of human papillomavirus L2.
Gambhira R; Karanam B; Jagu S; Roberts JN; Buck CB; Bossis I; Alphs H; Culp T; Christensen ND; Roden RB
J Virol; 2007 Dec; 81(24):13927-31. PubMed ID: 17928339
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2.
Nakao S; Mori S; Kondo K; Matsumoto K; Yoshikawa H; Kanda T
Virology; 2012 Dec; 434(1):110-7. PubMed ID: 23051711
[TBL] [Abstract][Full Text] [Related]
26. Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types.
Zhang T; Liu H; Chen X; Wang Z; Wang S; Qu C; Zhang J; Xu X
Vaccine; 2016 Nov; 34(46):5531-5539. PubMed ID: 27729176
[TBL] [Abstract][Full Text] [Related]
27. Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies.
Wang JW; Jagu S; Kwak K; Wang C; Peng S; Kirnbauer R; Roden RB
Virology; 2014 Jan; 449():304-16. PubMed ID: 24418565
[TBL] [Abstract][Full Text] [Related]
28. Phosphorylation of Human Papillomavirus Type 16 L2 Contributes to Efficient Virus Infectious Entry.
Broniarczyk J; Massimi P; Pim D; Bergant Marušič M; Myers MP; Garcea RL; Banks L
J Virol; 2019 Jul; 93(13):. PubMed ID: 30996086
[TBL] [Abstract][Full Text] [Related]
29. Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31.
Fleury MJ; Touzé A; Alvarez E; Carpentier G; Clavel C; Vautherot JF; Coursaget P
Arch Virol; 2006 Aug; 151(8):1511-23. PubMed ID: 16508703
[TBL] [Abstract][Full Text] [Related]
30. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
[TBL] [Abstract][Full Text] [Related]
31. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.
Roden RB; Weissinger EM; Henderson DW; Booy F; Kirnbauer R; Mushinski JF; Lowy DR; Schiller JT
J Virol; 1994 Nov; 68(11):7570-4. PubMed ID: 7523700
[TBL] [Abstract][Full Text] [Related]
32. Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies.
Carpentier GS; Fleury MJ; Touzé A; Sadeyen JR; Tourne S; Sizaret PY; Coursaget P
J Med Virol; 2005 Dec; 77(4):558-65. PubMed ID: 16254978
[TBL] [Abstract][Full Text] [Related]
33. Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody.
Wang D; Li Z; Xiao J; Wang J; Zhang L; Liu Y; Fan F; Xin L; Wei M; Kong Z; Yu H; Gu Y; Zhang J; Li S; Xia N
PLoS One; 2015; 10(4):e0123944. PubMed ID: 25905781
[TBL] [Abstract][Full Text] [Related]
34. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6.
Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
J Virol; 1999 Jul; 73(7):6188-90. PubMed ID: 10364381
[TBL] [Abstract][Full Text] [Related]
35. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies.
Christensen ND; Dillner J; Eklund C; Carter JJ; Wipf GC; Reed CA; Cladel NM; Galloway DA
Virology; 1996 Sep; 223(1):174-84. PubMed ID: 8806551
[TBL] [Abstract][Full Text] [Related]
36. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies.
Kawana K; Kawana Y; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
Vaccine; 2001 Jan; 19(11-12):1496-502. PubMed ID: 11163673
[TBL] [Abstract][Full Text] [Related]
37. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin.
Rubio I; Bolchi A; Moretto N; Canali E; Gissmann L; Tommasino M; Müller M; Ottonello S
Vaccine; 2009 Mar; 27(13):1949-56. PubMed ID: 19368776
[TBL] [Abstract][Full Text] [Related]
38. Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies.
Xie X; Liu Y; Zhang T; Xu Y; Bao Q; Chen X; Liu H; Xu X
Arch Virol; 2013 Jan; 158(1):193-9. PubMed ID: 22965579
[TBL] [Abstract][Full Text] [Related]
39. Encapsidating artificial human papillomavirus-16 mE7 protein in human papillomavirus-6b L1/L2 virus like particles.
Xu YF; Wang QY; Zhang HT; Han YH; Song GX; Xu XM
Chin Med J (Engl); 2007 Mar; 120(6):503-8. PubMed ID: 17439745
[TBL] [Abstract][Full Text] [Related]
40. Role of L2 cysteines in papillomavirus infection and neutralization.
Gambhira R; Jagu S; Karanam B; Day PM; Roden R
Virol J; 2009 Oct; 6():176. PubMed ID: 19860897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
